Translational Development Acquisition Corp.

Translational Development Acquisition Corp., whose warrants trade on the Nasdaq under the ticker TDACW, filed a Form 10-Q with the Securities and Exchange Commission on May 15, 2025, covering its most recent fiscal quarter. The blank-check company focuses on the life sciences and translational medicine sector, targeting businesses engaged in moving scientific discoveries from research into clinical and commercial applications. The quarterly filing indicates the company remains in its search phase, continuing to evaluate potential business combination targets within the healthcare and biotech landscape. Full sponsor details and transaction history are available in the complete filing record. For deeper analytics, filings history, and deal-flow alerts on Translational Development Acquisition Corp. and hundreds of other active SPACs, sign up for full data access at SpacDesk.